DIEBOLD NIXDORF INC (DBD) Stock Fundamental Analysis
USA - NYSE:DBD - US2536512021 - Common Stock
57.54 USD
+0.65 (+1.14%)
57.54 USD
0 (0%)
DBD gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 33 industry peers in the Technology Hardware, Storage & Peripherals industry. Both the profitability and the financial health of DBD get a neutral evaluation. Nothing too spectacular is happening here. DBD is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year DBD was profitable.
DBD had a positive operating cash flow in the past year.
DBD had negative earnings in 4 of the past 5 years.
In multiple years DBD reported negative operating cash flow during the last 5 years.
1.2 Ratios
With a Return On Assets value of -0.34%, DBD perfoms like the industry average, outperforming 57.58% of the companies in the same industry.
DBD has a better Return On Equity (-1.18%) than 69.70% of its industry peers.
DBD has a Return On Invested Capital of 8.61%. This is in the better half of the industry: DBD outperforms 66.67% of its industry peers.
The Average Return On Invested Capital over the past 3 years for DBD is significantly below the industry average of 14.92%.
The 3 year average ROIC (5.12%) for DBD is below the current ROIC(8.61%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.34% | ||
| ROE | -1.18% | ||
| ROIC | 8.61% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
1.3 Margins
DBD has a better Operating Margin (7.32%) than 72.73% of its industry peers.
DBD's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 25.44%, DBD is doing worse than 60.61% of the companies in the same industry.
In the last couple of years the Gross Margin of DBD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.32% | ||
| PM (TTM) | N/A | ||
| GM | 25.44% |
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so DBD is destroying value.
Compared to 1 year ago, DBD has about the same amount of shares outstanding.
DBD has less shares outstanding than it did 5 years ago.
DBD has a better debt/assets ratio than last year.
2.2 Solvency
DBD has an Altman-Z score of 1.84. This is not the best score and indicates that DBD is in the grey zone with still only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 1.84, DBD perfoms like the industry average, outperforming 45.45% of the companies in the same industry.
The Debt to FCF ratio of DBD is 4.62, which is a neutral value as it means it would take DBD, 4.62 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.62, DBD is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
A Debt/Equity ratio of 0.85 indicates that DBD is somewhat dependend on debt financing.
The Debt to Equity ratio of DBD (0.85) is worse than 63.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.85 | ||
| Debt/FCF | 4.62 | ||
| Altman-Z | 1.84 |
ROIC/WACC0.91
WACC9.44%
2.3 Liquidity
A Current Ratio of 1.36 indicates that DBD should not have too much problems paying its short term obligations.
DBD has a Current ratio (1.36) which is in line with its industry peers.
DBD has a Quick Ratio of 1.36. This is a bad value and indicates that DBD is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.91, DBD perfoms like the industry average, outperforming 54.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.91 |
3. Growth
3.1 Past
DBD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.20%, which is quite good.
DBD shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 69.69% yearly.
Looking at the last year, DBD shows a decrease in Revenue. The Revenue has decreased by -3.75% in the last year.
Measured over the past years, DBD shows a decrease in Revenue. The Revenue has been decreasing by -3.18% on average per year.
EPS 1Y (TTM)13.2%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%-18.26%
Revenue 1Y (TTM)-3.75%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%-2.61%
3.2 Future
Based on estimates for the next years, DBD will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.87% on average per year.
DBD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.83% yearly.
EPS Next Y-9.47%
EPS Next 2Y12.54%
EPS Next 3Y11.87%
EPS Next 5YN/A
Revenue Next Year2.09%
Revenue Next 2Y2.41%
Revenue Next 3Y2.83%
Revenue Next 5YN/A
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
DBD is valuated rather expensively with a Price/Earnings ratio of 20.33.
Based on the Price/Earnings ratio, DBD is valued a bit cheaper than 75.76% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.41, DBD is valued a bit cheaper.
Based on the Price/Forward Earnings ratio of 11.77, the valuation of DBD can be described as reasonable.
Compared to the rest of the industry, the Price/Forward Earnings ratio of DBD indicates a somewhat cheap valuation: DBD is cheaper than 78.79% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.87, DBD is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.33 | ||
| Fwd PE | 11.77 |
4.2 Price Multiples
96.97% of the companies in the same industry are more expensive than DBD, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, DBD is valued cheaper than 81.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.45 | ||
| EV/EBITDA | 6.72 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.54%
EPS Next 3Y11.87%
5. Dividend
5.1 Amount
DBD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
57.54
+0.65 (+1.14%)
Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)
Earnings (Next)
Inst Owners106.19%
Inst Owner Change-3.27%
Ins Owners1.75%
Ins Owner Change0.24%
Market Cap2.11B
Analysts82.86
Price Target77.18 (34.13%)
Short Float %2.04%
Short Ratio3.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.65%
Min EPS beat(2)1.76%
Max EPS beat(2)59.55%
EPS beat(4)2
Avg EPS beat(4)0.05%
Min EPS beat(4)-52.17%
Max EPS beat(4)59.55%
EPS beat(8)5
Avg EPS beat(8)9.34%
EPS beat(12)7
Avg EPS beat(12)-88.46%
EPS beat(16)8
Avg EPS beat(16)-91.11%
Revenue beat(2)1
Avg Revenue beat(2)0.84%
Min Revenue beat(2)-1.34%
Max Revenue beat(2)3.02%
Revenue beat(4)1
Avg Revenue beat(4)-0.11%
Min Revenue beat(4)-1.34%
Max Revenue beat(4)3.02%
Revenue beat(8)4
Avg Revenue beat(8)0.04%
Revenue beat(12)4
Avg Revenue beat(12)-0.96%
Revenue beat(16)4
Avg Revenue beat(16)-2.35%
PT rev (1m)4.61%
PT rev (3m)4.61%
EPS NQ rev (1m)-2.88%
EPS NQ rev (3m)-10.62%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.42%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.82%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.33 | ||
| Fwd PE | 11.77 | ||
| P/S | 0.57 | ||
| P/FCF | 10.45 | ||
| P/OCF | 9.31 | ||
| P/B | 1.92 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.72 |
EPS(TTM)2.83
EY4.92%
EPS(NY)4.89
Fwd EY8.5%
FCF(TTM)5.5
FCFY9.56%
OCF(TTM)6.18
OCFY10.75%
SpS100.25
BVpS29.95
TBVpS-9.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.34% | ||
| ROE | -1.18% | ||
| ROCE | 10.9% | ||
| ROIC | 8.61% | ||
| ROICexc | 9.77% | ||
| ROICexgc | 29.69% | ||
| OM | 7.32% | ||
| PM (TTM) | N/A | ||
| GM | 25.44% | ||
| FCFM | 5.49% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
ROICexc(3y)6.13%
ROICexc(5y)6.88%
ROICexgc(3y)21.8%
ROICexgc(5y)29.05%
ROCE(3y)6.48%
ROCE(5y)7.06%
ROICexcg growth 3Y-11.73%
ROICexcg growth 5Y37.89%
ROICexc growth 3Y4.77%
ROICexc growth 5Y35.34%
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
F-Score4
Asset Turnover0.98
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.85 | ||
| Debt/FCF | 4.62 | ||
| Debt/EBITDA | 2.31 | ||
| Cap/Depr | 18.6% | ||
| Cap/Sales | 0.68% | ||
| Interest Coverage | 2.84 | ||
| Cash Conversion | 56.26% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.91 | ||
| Altman-Z | 1.84 |
F-Score4
WACC9.44%
ROIC/WACC0.91
Cap/Depr(3y)16.93%
Cap/Depr(5y)15.92%
Cap/Sales(3y)0.61%
Cap/Sales(5y)0.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.2%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%-18.26%
EPS Next Y-9.47%
EPS Next 2Y12.54%
EPS Next 3Y11.87%
EPS Next 5YN/A
Revenue 1Y (TTM)-3.75%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%-2.61%
Revenue Next Year2.09%
Revenue Next 2Y2.41%
Revenue Next 3Y2.83%
Revenue Next 5YN/A
EBIT growth 1Y3.35%
EBIT growth 3Y19.17%
EBIT growth 5Y36.19%
EBIT Next Year24.02%
EBIT Next 3Y13.05%
EBIT Next 5YN/A
FCF growth 1Y145.49%
FCF growth 3Y8.67%
FCF growth 5Y113.09%
OCF growth 1Y154.49%
OCF growth 3Y6.68%
OCF growth 5Y26.59%